Shire PLC (SHPG) Receives Buy Rating from Shore Capital
Several other research analysts have also recently issued reports on the stock. Goldman Sachs Group Inc. reaffirmed a buy rating on shares of Shire PLC in a report on Tuesday, June 28th. Jefferies Group reaffirmed a buy rating and issued a $262.00 target price on shares of Shire PLC in a report on Wednesday, September 7th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Shire PLC in a report on Monday, September 26th. TheStreet cut shares of Shire PLC to a hold rating in a report on Thursday, August 4th. Finally, Citigroup Inc. reaffirmed a buy rating on shares of Shire PLC in a report on Friday, July 15th. Five analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $232.75.
Shire PLC (NASDAQ:SHPG) opened at 194.50 on Friday. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The stock has a market cap of $57.93 billion, a P/E ratio of 40.42 and a beta of 1.16. The stock has a 50 day moving average of $195.56 and a 200 day moving average of $187.04.
Shire PLC (NASDAQ:SHPG) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.35. The business earned $2.43 million during the quarter, compared to analysts’ expectations of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The business’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.63 earnings per share. Equities analysts anticipate that Shire PLC will post $12.92 EPS for the current fiscal year.
The company also recently declared a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were issued a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Institutional investors have recently modified their holdings of the stock. Canal Insurance CO bought a new position in Shire PLC during the second quarter valued at approximately $102,000. FTB Advisors Inc. increased its position in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. bought a new position in Shire PLC during the second quarter valued at approximately $111,000. Quadrant Capital Group LLC increased its position in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the period. Finally, Ropes Wealth Advisors LLC bought a new position in Shire PLC during the second quarter valued at approximately $114,000. 24.26% of the stock is currently owned by institutional investors and hedge funds.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.